Compounded tirzepatide: the dual-hormone GLP-1, explained

Compounded tirzepatide is tirzepatide, a medicine that acts on two gut-hormone receptors, GIP and GLP-1, prepared with vitamin B12 by a state-licensed 503A pharmacy for one patient’s prescription. It is a weekly injection. It is compounded and not FDA-approved, and it is not Zepbound® or Mounjaro®. Through VevaMD a board-certified physician decides whether it fits you, at one monthly price that includes your care.

Compounded, not FDA-approvedWeekly injection, with vitamin B12

See if compounded tirzepatide fits me →

A board-certified, US-licensed physician reviews every intake.

What Compounded tirzepatide costs at VevaMD

  • As low as $299/mo. Includes physician review, medication and shipping. Same price at every dose.
  • No membership fee for compounded GLP-1; brand Wegovy® and Zepbound® have a VevaMD membership, and you pay the manufacturer for the medication. No contract; cancel anytime on My VevaMD. Full refund if not prescribed. HSA & FSA eligible. Labs, if your physician orders them, are billed separately and shown before you pay.
  • You see your price before you pay. Full refund if not prescribed.

Compounded medications are prepared by state-licensed pharmacies for individual patients. They are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality.

What compounded tirzepatide is

Tirzepatide is one molecule that acts on the receptors for two hormones the gut releases after a meal, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 [1]. Compounded tirzepatide is that ingredient prepared by a pharmacist in a state-licensed pharmacy for a single prescription [2]. Through VevaMD it comes with vitamin B12 in the same vial and is prepared by NewLife Rx, a 503A pharmacy, after a physician has reviewed your intake and prescribed it.

Be clear on what it is not. It is not FDA-approved: compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are sold [2]. It is not Zepbound® or Mounjaro®, the tirzepatide products Eli Lilly makes, and it is not a generic of either, because a generic is itself an FDA-approved drug [2]. Lilly’s trial numbers describe Lilly’s products, so you will not find them on this page.

Why people choose it through VevaMD

  • A physician, start to finish. A board-certified, US-licensed physician reads your intake, asks follow-up questions when needed, and decides. A prescription is never guaranteed, and if you are not prescribed, your first payment is refunded.
  • You know exactly who made it. The FDA has found fake compounded tirzepatide sold with labels naming pharmacies that never made it [3]. VevaMD names its pharmacy up front: NewLife Rx, state-licensed and overseen by its state board of pharmacy [2].
  • A price that holds. As low as $299/mo, including the physician, the medication and shipping, at every dose. Compounded plans have no membership fee.
  • Follow-up built in. As the amount rises, your physician adjusts the plan with you, and the VevaMD team handles orders, shipping and questions.
  • Nothing unapproved. The FDA says retatrutide and cagrilintide cannot be used in compounding under federal law [3]. VevaMD does not prescribe them.

Who it may be for, and who it is not for

May be for

  • Adults whose BMI is 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes [4]
  • People for whom diet and activity alone have not been enough; the Endocrine Society describes weight-management medicines as adjuncts to those changes, not replacements [5]
  • People who are fine with a weekly self-injection from a vial
  • People who want one monthly price for care and medication, with no separate pharmacy bill

Not for

  • Anyone with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2 [1]
  • Anyone who has had a serious allergic reaction to tirzepatide [1]
  • Anyone who is pregnant [1]
  • Anyone already taking another tirzepatide product or a GLP-1 medicine; the Zepbound® label advises against combining them [1]
  • People with severe gastroparesis [1]

How tirzepatide works

GLP-1 regulates appetite and calorie intake. Tirzepatide adds a second signal: according to the Zepbound® label, studies outside people suggest GIP may further contribute to how much you eat, and receptors for both hormones sit in the brain areas that control appetite [1]. The molecule carries a fatty-acid chain that binds it to a blood protein, which is why one injection lasts a week. It also slows stomach emptying, most after the first injection and less over time [1].

Treatment starts at a low amount and steps up gradually. Going slowly is how stomach side effects are kept in check, and the Obesity Medicine Association describes the same approach for these medicines [6]. Your physician decides when to step up, when to hold, and when you have reached the right amount.

Each shipment is a small vial of liquid. Draw every weekly amount into a fresh, sterile syringe; never reuse a needle. The FDA advises against using any injectable GLP-1 that arrives warm, and against using a multi-dose vial more than 28 days after first opening it [3].

What the first months look like

  1. Day oneYou answer the intake online. A physician licensed in your state reviews it, and you see your price before you pay.
  2. Weeks 1 to 4The lowest amount. This is when nausea, diarrhea, constipation and a smaller appetite tend to show up first [6].
  3. Months 2 to 5Step-ups, each one only if the last was tolerated. Your physician may hold you at a step for longer; the monthly price stays the same either way.
  4. After 12 weeks on the full amountThe checkpoint NIDDK describes for weight-management medicines: whether you have lost at least 5% of your starting weight, and whether to continue or change the plan [4].
  5. Year one and beyondTreatment for obesity is long-term. NIDDK says weight usually returns in part after a medicine is stopped, and that a health care professional may advise staying on one that works [4].

Side effects and the boxed warning

There is no FDA label for compounded tirzepatide. What follows comes from the label for Zepbound®, Eli Lilly’s FDA-approved tirzepatide, and describes the ingredient’s known risks.

  • Common: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection-site reactions, tiredness, burping, hair loss and heartburn [1].
  • Serious: severe stomach side effects, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar with insulin or a sulfonylurea, and worsening diabetic eye disease in people with type 2 diabetes [1].
  • Anesthesia: because it slows the stomach, tell the team before any surgery or sedation that you take it [1].

The FDA has also received reports of side effects in people given compounded tirzepatide at doses above those on the approved label, or stepped up faster [3]; your physician’s plan follows a gradual schedule for that reason.

The rules for compounded tirzepatide

Tirzepatide injection was in shortage until December 19, 2024, when the FDA declared the shortage resolved; after a transition for state-licensed pharmacies, compounding no longer depends on that shortage [7]. Today a 503A pharmacy prepares tirzepatide for an individual patient’s prescription, overseen by its state board of pharmacy [2]. In April 2026 the FDA proposed excluding tirzepatide from the bulk-ingredient list for 503B outsourcing facilities, the large-scale compounders; 503A pharmacies are a different category [8].

VevaMD follows the FDA’s rules for how telehealth companies describe a compounded GLP-1: never calling it FDA-approved, never claiming trials show it matches a brand, and naming its pharmacy, NewLife Rx, up front [9]. (The FDA’s stated view is that compounded drugs are meant for patients whose needs an FDA-approved drug cannot meet [2]; Zepbound® is offered through the same intake.)

Tirzepatide next to the other options

One intake covers all four GLP-1 options, and the physician who reviews it recommends one. Compounded semaglutide acts on GLP-1 alone and has the lowest monthly price; Zepbound® is Lilly’s FDA-approved tirzepatide, and Wegovy® is Novo Nordisk’s semaglutide.

The four GLP-1 options at VevaMD
FDA statusHow it is takenHow you pay at VevaMDMain trade-offs
Compounded semaglutideCompounded, not FDA-approvedWeekly injection from a vial, with vitamin B12One monthly price, as low as $199/mo: physician, medication and shipping. No membership feeThe lowest monthly price, the same at every dose; you draw each dose with a syringe
Compounded tirzepatideCompounded, not FDA-approvedWeekly injection from a vial, with vitamin B12One monthly price, as low as $299/mo: physician, medication and shipping. No membership feeActs on two gut-hormone receptors, GLP-1 and GIP; the same price at every dose; you draw each dose with a syringe
Wegovy®FDA-approved brandWeekly prefilled pen, or a daily tabletA $149/mo VevaMD membership, plus the self-pay price paid to Novo Nordisk ($348–$498/mo in total for the pen)Approved for weight and to lower heart risk in adults with heart disease; pen or pill; two separate charges
Zepbound®FDA-approved brandWeekly prefilled penA $149/mo VevaMD membership, plus the self-pay price paid to Eli Lilly ($448–$598/mo in total)Approved for weight and for moderate to severe sleep apnea with obesity; prefilled pen; two separate charges

Weight gain in perimenopause and menopause

Many women notice their body changing shape in their late 40s even when the scale barely moves. A large study of midlife women (SWAN) found that at the start of the menopause transition the rate of fat gain doubled and lean mass began to fall, while weight rose at the same steady pace as before [10]. The Menopause Society adds that falling estrogen pushes fat toward the abdomen [11].

Common questions

Does tirzepatide affect birth control pills?

It can. The Zepbound label advises women on birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each increase. Patches, rings, IUDs and implants are not affected.

Is compounded tirzepatide the same price at every dose?

Yes. Through VevaMD, compounded tirzepatide is one monthly price whatever amount your physician prescribes, including the physician review, the medication and shipping, with no membership fee.

How is tirzepatide different from semaglutide?

Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors. Which fits you is a physician decision based on your history, how you handle side effects, and price; one VevaMD intake covers both.

Can I get retatrutide instead?

No. The FDA says retatrutide cannot be used in compounding under federal law, and it is not an FDA-approved drug. VevaMD does not prescribe it.

Who makes the compounded tirzepatide I would receive?

NewLife Rx, a state-licensed 503A pharmacy, prepares it for your prescription and ships it to you. VevaMD does not make medication, and Eli Lilly does not make compounded tirzepatide.

Can I move from compounded tirzepatide to Zepbound?

Yes. Your VevaMD physician can prescribe Zepbound, Eli Lilly’s FDA-approved tirzepatide pen, through a VevaMD membership, and you pay Eli Lilly for the medication.

A physician decides what fits you

See if compounded tirzepatide fits me →

One private online intake covers every GLP-1 option. You see your price before you pay, and your first payment is refunded in full if nothing is prescribed.

Sources

  1. ZEPBOUND® (tirzepatide) injection prescribing information. Eli Lilly. DailyMed, revised September 2026. Checked October 28, 2026.
  2. FDA. Compounding and the FDA: questions and answers (content current as of September 16, 2025). Checked October 28, 2026.
  3. FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). Checked October 28, 2026.
  4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription medications to treat overweight and obesity. Checked October 28, 2026.
  5. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. Checked October 28, 2026.
  6. Obesity Medicine Association. Weight loss medication side effects: know before you start. January 20, 2024. Checked October 28, 2026.
  7. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updates of December 19, 2024 and February 21, 2025). Checked October 28, 2026.
  8. FDA. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. News release, April 30, 2026. Checked October 28, 2026.
  9. FDA. FDA to telehealth companies: what to know when promoting compounded drugs (content current as of June 15, 2026). Checked October 28, 2026.
  10. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. Checked October 28, 2026.
  11. The Menopause Society. MenoNote: Midlife weight gain. Checked October 28, 2026.

Last updated . Content standards

Clinical care is provided by board-certified, US-licensed physicians. VevaMD Inc is a technology and marketing storefront only — not a medical provider or a pharmacy. Medications are dispensed by licensed U.S. partner pharmacies after a valid prescription. Compounded medications are prepared by state-licensed pharmacies for individual patients. They are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality. Wegovy®, Ozempic®, Zepbound® and Mounjaro® are trademarks of their owners. VevaMD is not affiliated with Novo Nordisk or Eli Lilly. This page is general information, not medical advice. A prescription is not guaranteed, and outcomes differ from person to person. Report a side effect to FDA MedWatch.